Valentina Sancisi

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 7

Top Venues

Oncogene

Nature communications

Cancers

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, Elisabetta Sauta, Federica Torricelli, Veronica Manicardi, Eleonora Zanetti, Stefania Orecchioni, Paolo Falvo, Simonetta Piana, Filippo Lococo, Massimiliano Paci, Francesco Bertolini, Alessia Ciarrocchi, Valentina Sancisi
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3. Nature communications 15 (1) (2024)
Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, Elisabetta Sauta, Federica Torricelli, Veronica Manicardi, Eleonora Zanetti, Stefania Orecchioni, Paolo Falvo, Simonetta Piana, Filippo Lococo, Massimiliano Paci, Francesco Bertolini, Alessia Ciarrocchi, Valentina Sancisi
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3. Nature communications 15 (1) (2024)
Giulia Gobbi, Alessandra Grieco, Federica Torricelli, Elisabetta Sauta, Giacomo Santandrea, Eleonora Zanetti, Valentina Fantini, Francesca Reggiani, Silvia Strocchi, Massimiliano Paci, Manik Vohra, Srinivas Vinod Saladi, Davide Carlo Ambrosetti, Alessia Ciarrocchi, Valentina Sancisi
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling. Cell death & disease 14 (11) (2023)
Silvia Strocchi, Francesca Reggiani, Giulia Gobbi, Alessia Ciarrocchi, Valentina Sancisi
The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation. Oncogene 41 (29) (2022)
Francesca Reggiani, Elisabetta Sauta, Federica Torricelli, Eleonora Zanetti, Elena Tagliavini, Giacomo Santandrea, Giulia Gobbi, Giovanna Damia, Riccardo Bellazzi, Davide Ambrosetti, Alessia Ciarrocchi, Valentina Sancisi
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma. Molecular cancer 20 (1) (2021)
Elisabetta Sauta, Francesca Reggiani, Federica Torricelli, Eleonora Zanetti, Elena Tagliavini, Giacomo Santandrea, Giulia Gobbi, Silvia Strocchi, Massimiliano Paci, Giovanna Damia, Riccardo Bellazzi, Davide Ambrosetti, Alessia Ciarrocchi, Valentina Sancisi
CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer. Cancers 13 (14) (2021)
Giulia Gobbi, Benedetta Donati, Italo Faria Do Valle, Francesca Reggiani, Federica Torricelli, Daniel Remondini, Gastone Castellani, Davide Carlo Ambrosetti, Alessia Ciarrocchi, Valentina Sancisi
The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene 38 (42) (2019)
Moira Ragazzi, Alessia Ciarrocchi, Valentina Sancisi, Greta Gandolfi, Alessandra Bisagni, Simonetta Piana
Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. International journal of endocrinology 2014 (2014)

Valentina Sancisi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Valentina Sancisi